Saleh Mohammad I, Bani Melhim Suhad
School of Pharmacy, The University of Jordan , Amman , Jordan.
J Chemother. 2019 Sep;31(5):274-283. doi: 10.1080/1120009X.2019.1609739. Epub 2019 May 9.
The objective of this project was to describe longitudinal change in chronic hepatitis C virologic reponse using time-to-event (TTE) analysis and to identify patient characteristics that determine the dynamics of this change. We compiled demographic, clinical, and genetic data from 715 chronic hepatitis C virus (HCV) patients treated with pegylated interferon (PEG-IFN) alfa-2a and ribavirin. TTE modelling described the time between antiviral treatment initiation and the first observation of undetectable HCV RNA. A lognormal TTE model was selected to describe time to first undetectable HCV RNA. The identified predictors of prolonged time to achieve undetectable HCV RNA include HCV genotype 1, low pre-treatment ALT level, older age, or with elevated baseline haemoglobin level. In conclusion, a cohort of patients with low probability of achieving SVR can be identified. This project identifies patients with a low risk of responding to PEG-IFN alfa-2a and ribavirin combination.
本项目的目的是使用事件发生时间(TTE)分析来描述慢性丙型肝炎病毒学反应的纵向变化,并确定决定这种变化动态的患者特征。我们收集了715例接受聚乙二醇化干扰素(PEG-IFN)α-2a和利巴韦林治疗的慢性丙型肝炎病毒(HCV)患者的人口统计学、临床和基因数据。TTE模型描述了抗病毒治疗开始至首次检测不到HCV RNA的时间。选择对数正态TTE模型来描述首次检测不到HCV RNA的时间。确定的实现HCV RNA检测不到时间延长的预测因素包括HCV 1型、治疗前ALT水平低、年龄较大或基线血红蛋白水平升高。总之,可以识别出一组实现持续病毒学应答(SVR)可能性较低的患者。本项目识别出了对PEG-IFNα-2a和利巴韦林联合治疗反应风险较低的患者。